Search results for: Pricing and Reimbursement

Competition through Innovation, Innovation through Competition

1 November 1998

…pharmaceutical industry’s output could instead be promoted by enhancing demand side pressures (informed payers and incentivised prescribers can get value for money) and by ensuring high rewards for breakthrough innovations….

Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly

18 July 2022

…A., Cubi-Molla, P. and Jofre-Bonet, M., 2022. Discontinuation of Performance-Based Financing in Primary Health Care: Impact on Family Planning and Maternal and Child Health. International Journal of Health Economics and…

About us

…healthcare efficiency, sustainability, and outcomes by: Generating original research and analysis For pragmatic solutions and stronger policy decisions. Promoting independent thinking To shape debate and create impact. Connecting industry and…

Turning around the NHS: Reflections on the 2025 OHE Annual Lecture

14 October 2025

…are expectations of affordability, accessibility, sustainability, and high quality – and demonstrated how the UK is struggling on nearly all of these metrics.  NHS performance: health outcomes, productivity, and public satisfaction…

Taking STRIDES: The value of diagnostics against AMR

10 June 2025

…and projecting public health: Spectrum value: Enables use of narrow-spectrum antibiotics by identifying specific pathogens and resistance patterns. Transmission value: Reduces the spread of infectious and resistant pathogens through earlier detection and…

Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds 

31 March 2026

…lived longer and in better health, and potentially billions saved to the global economy.”  Methodology  This report quantifies the total health and economic burdens of ASCVD, and subsequently the share of these burdens attributable…

Can we “Netflix” the Broken Antibiotics Market?

28 September 2022, 3:00pm

…NHS England to develop and test innovative models for the evaluation and purchase of antimicrobials. David Glover, Deputy Head of the Medicines Analysis Team at NHS England and Improvement David…

Around The World in HTAs: Italy – What’s Next?

20 April 2023

…of AIFA (National Medicines Agency), supported by a Technical Scientific Committee (CTS), that provides scientific advice to Price and Reimbursement (P&R) negotiations, and a P&R Committee (CPR), that negotiates the…

Climate action is health action: OHE’s focus on sustainability

22 July 2025

…improving the sustainability of clinical and funding decisions. Professor Briggs’ presentation addressed methodological challenges and opportunities for aligning the tools of health and environmental economics – towards more coherent and…